Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of Satralizumab in MOGAD
2023-507196-22-00Phase 3Authorised
- Sponsor
- Roche
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) comparing Satralizumab arm with Placebo arm (2 arms). Primary endpoint: Time to first adjudicated MOGAD relapse. Planned start Jan 2024; status: authorised.
02
Drugs
satralizumab
03
Conditions
myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)
Beyond the preview
Go deeper on 2023-507196-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507196-22-00.